Comtan Patent Expiration

Comtan is a drug owned by Orion Pharma. It is protected by 2 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Sep 14, 2018. Details of Comtan's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6599530 Oral compacted composition comprising catechol derivatives
Sep, 2018

(6 years ago)

Expired
US5446194 Pharmacologically active catechol derivatives
Oct, 2013

(10 years ago)

Expired

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Comtan is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Comtan's family patents as well as insights into ongoing legal events on those patents.

Comtan's Family Patents


Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Comtan's generic launch date based on the expiry of its last outstanding patent is estimated to be Sep 14, 2018 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Comtan Generics:

Entacapone is the generic name for the brand Comtan. 8 different companies have already filed for the generic of Comtan, with Ajanta Pharma Ltd having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Comtan's generic

How can I launch a generic of Comtan before its drug patent expiration? :

You can seek FDA approval to launch a generic drug before the expiration of Comtan's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Comtan's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Given below are the details of the already filed Para IV certificates on Comtan -

Strength Submission Date ANDA(s) Filed First applicant approval Last patent expiry 180 day status
200 mg 11 Apr, 2007 1 16 Aug, 2012 14 Sep, 2018 Extinguished

Alternative Brands for Comtan

Comtan which is used for treating Parkinson's disease., has several other brand drugs in the same treatment category and using the same active ingredient (Entacapone). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.

Drug Owner Drug Name Treatment Area
Bausch
Tasmar Used for managing symptoms of Parkinson's disease.
Boehringer Ingelheim
Mirapex Er Used for managing symptoms of Parkinson's disease.
Impax
Rytary Used for treating Parkinson's disease and related conditions such as post-encephalitic parkinsonism and parkinsonism from carbon monoxide or manganese intoxication.
Orion Pharma
Stalevo 50

(uses Entacapone)

Used for managing symptoms of Parkinson's disease.
Stalevo 75

(uses Entacapone)

Used for managing symptoms of Parkinson's Disease.
Stalevo 100

(uses Entacapone)

Used for managing symptoms of Parkinson's disease.
Stalevo 125

(uses Entacapone)

used for managing symptoms of Parkinson's Disease.
Stalevo 150

(uses Entacapone)

Used for managing symptoms of Parkinson's disease.
Stalevo 200

(uses Entacapone)

Used for managing the symptoms of Parkinson's disease.
Supernus Pharms
Osmolex Er Used for treating Parkinson's disease and drug-induced extrapyramidal reactions in adult patients.
Teva
Azilect Used for managing the symptoms of Parkinson's disease.

Apart from brand drugs containing the same ingredient, some generics have also been filed for Entacapone, Comtan's active ingredient. Check the complete list of approved generic manufacturers for Comtan





About Comtan

Comtan is a drug owned by Orion Pharma. It is used for treating Parkinson's disease. Comtan uses Entacapone as an active ingredient. Comtan was launched by Orion Pharma in 1999.

Approval Date:

Comtan was approved by FDA for market use on 19 October, 1999.

Active Ingredient:

Comtan uses Entacapone as the active ingredient. Check out other Drugs and Companies using Entacapone ingredient

Treatment:

Comtan is used for treating Parkinson's disease.

Dosage:

Comtan is available in tablet form for oral use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
200MG TABLET Prescription ORAL